EXACT Sciences Corporation (NASDAQ: EXAS ) Q2 2014 Earnings Conference Call July 22, 2014 10:00 AM ET ..... Presentation Operator Good day, ladies and gentlemen, welcome to the Exact Sciences Second Quarter 2014 Earnings Conference Call. At this time
Exact Sciences (NASDAQ: EXAS ) Q2 results : Revenues: $0; R&D Expense: $7.2M (+11.1%); SG&A Expense: $12.4M (+78.9%); Operating
Exact Sciences (NASDAQ: EXAS ): Q2 EPS of -$0.24 in-line. Press Release Post your comment!
ABG , AMTD , AOS , ARMH , ATI , BTU , CIT , CMCSA , CNC , COL , CS , CSL , DD , DFRG , DPZ , EDU , EXAS , FMER , GCI , HOG , HUB.B , IR , KMB , KO , LMT , LPT , LXK , MCD , MJN , MO , MOSY , NEOG , OMC , PII , PLD , RESI , RF , SAH
ancillary-benefit suppliers MET, UNM ; PBMs CVS, ESRX ; managed-care providers AET, UNH, CI ; pg 17]; Exact Sciences [ EXAS ; impending FDA approval of its colon cancer screening test; pg 19]; REITs with DC office exposure [ BDN
North Dakota and Western Canada should grow 10% per year over the next 3 years. In our opinion, North D akota, O klahoma and T exas are critical states from a production, pipeline route, storage and end-market consumption perspective. We believe these states
favorable trials of muscular dystrophy drug; pg 18); Viacom ( VIA/VIAB ; pg 21); Brink’s ( BCO ; pg 22); Exact Sciences ( EXAS ; DNA-based Cologuard test trials appear promising; pg 25); Walgreen ( WAG ; 5-yr valuation low; pg 34